Skip to main content
Retour
Watch Compare

Lexaria Bioscience Corp.

Qualité des données : 100%
LEXX
Nasdaq Manufacturing Chemicals
0,94 €
▼ 0,01 € (-1,12%)
Cap. Boursière: 23,51 M
Prix
0,94 €
Cap. Boursière
23,51 M
Fourchette du Jour
0,94 € — 0,99 €
Fourchette 52 Semaines
0,46 € — 1,69 €
Volume
60 818
Ouverture 0,97 €
Moyenne 50J / 200J
0,74 €
28,19% above
Moyenne 50J / 200J
0,89 €
6,67% above

Quick Summary

Points Clés

Revenue declined -0,59% annually over 5 years
Negative free cash flow of -8,71 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 52,64%
Capital efficient — spends only 0,00% of revenue on capex

Croissance

Revenue Growth (5Y)
-0,59%
En dessous de la moyenne du secteur (1,82%)
Revenue (1Y)52,05%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-206,27%
En dessous de la moyenne du secteur (-53,41%)
ROIC-172,70%
Net Margin-2067,65%
Op. Margin-2062,00%

Sécurité

Debt / Equity
N/A
Current Ratio3,68
Interest CoverageN/A

Valorisation

PE (TTM)
-2,18
En dessous de la moyenne du secteur (-1,48)
P/B Ratio4,78
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -2,2 -1,5
P/B 4,8 1,6
ROE % -206,3 -53,4
Net Margin % -2067,7 -41,5
Rev Growth 5Y % -0,6 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 52,05% Revenue Growth (3Y) 76,65%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -0,59% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 522 000,0 Net Income (TTM) -10,79 M
ROE -206,27% ROA -168,75%
Gross Margin 100,00% Operating Margin -2062,00%
Net Margin -2067,65% Free Cash Flow (TTM) -8,71 M
ROIC -172,70% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 3,68
Interest Coverage N/A Asset Turnover 0,08
Working Capital 3,91 M Tangible Book Value 4,60 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2,18 Forward P/E N/A
P/B Ratio 4,78 P/S Ratio 45,03
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -37,05%
Market Cap 23,51 M Enterprise Value 19,21 M
Per Share
EPS (Diluted TTM) -0,57 Revenue / Share 0,02
FCF / Share -0,35 OCF / Share -0,35
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,00% FCF Conversion 80,68%
SBC-Adj. FCF -9,52 M Growth Momentum 52,64

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 705 923,0 464 278,0 226 208,0 255 397,0 722 738,0
Net Income -11,90 M -5,80 M -6,66 M -7,27 M -4,19 M
EPS (Diluted) -0,66 -0,47 — — —
Gross Profit 703 203,0 459 456,0 194 708,0 183 556,0 547 392,0
Operating Income -11,88 M -5,75 M -6,53 M -7,38 M —
EBITDA — — — — —
R&D Expenses 8,24 M 2,36 M 3,67 M 1,84 M 1,26 M
SG&A Expenses — — — — —
D&A 51 225,0 76 153,0 145 397,0 102 718,0 —
Interest Expense — 7 760,0 — — —
Income Tax — — — 0,0 6 093,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 4,18 M 8,87 M 3,08 M 7,83 M 13,27 M
Total Liabilities 1,57 M 1,21 M 403 908,0 201 437,0 203 265,0
Shareholders' Equity 2,99 M 8,04 M 3,04 M 7,95 M 13,06 M
Total Debt — — — — —
Cash & Equivalents — — — 5,81 M 10,92 M
Current Assets 3,47 M 7,90 M 2,20 M 6,98 M 12,44 M
Current Liabilities 1,49 M 1,10 M 267 735,0 194 036,0 153 276,0